Antibody Drug Discovery - Continuous Innovative Drug Discovery

Tatsuro Kosaka appointed as Representative Director, Chairman and Osamu Okuda appointed as Representative Director, President (Mar.)

Announced CHUGAI DIGITAL VISION 2030 to Accelerate Digital Transformation (Mar.)

Approval of Enspryng®, a pH-Dependent Binding Humanized anti-IL-6 Receptor Monoclonal Antibody, in the United States (Aug.)

Launched Enspryng®, a pH-Dependent Binding Humanized anti-IL-6 Receptor Monoclonal Antibody (Aug.)

Integration and Reorganization of Chugai Business Support Co., Ltd. and Medical Culture Inc., under a new trade name of Chugai Business Solution Co., Ltd. (Jan.)

Osamu Okuda appointed as Representative Director and President (Mar.)

Dissolution of Forerunner Pharma Research (Mar.)

Launched Polivy®, an anticancer agent/an antimicrotubule binding anti-CD79b monoclonal antibody (May)

Regulatory approval of Ronapreve®, an anti-SARS-CoV-2 monoclonal antibody (Jul.)

Launched FoundationOne® Liquid CDx Cancer Genomic Profile, a diagnostic program (Aug.)

Launched Evrysdi® for the treatment of spinal muscular atrophy (Aug.)

Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for the treatment of severe COVID-19 in the Europe (Dec.)

Integration of Chugai Pharma Science (Beijing) Co., Ltd. and Chugai Pharma China Co., Ltd. (Feb.)

Launched Vabysmo®, an anti VEGF/anti Ang-2 bispecific antibody. Marks Chugai’s first full-scale entry in the field of ophthalmology (May)

Launched Edirol®, an active vitamin D3 derivative, in China (Jul.)

Partial revision of the Basic Alliance Agreement with Roche (Jul.)

MITCHGA®, an anti-IL-31 receptor a humanized monoclonal antibody created by Chugai, was launched in Japan by Maruho Co., Ltd. for the treatment of itching associated with atopic dermatitis (Aug.)

Construction completed for Chugai Life Science Park Yokohama (Yokohama Prefecture) (Oct.)

Fuji Gotemba Research Laboratories (Shizuoka) and Kamakura Research Laboratories (Kanagawa) closed (March)

Full-scale operation of Chugai Life Science Park Yokohama (April)

Launch of of HEMLIBRA®, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, for congenital hemophilia A without inhibitors in Taiwan (July)

Establishment of Chugai Venture Fund LLC in the United States (July)

Launch of Enspryng®, a pH-Dependent Binding Humanized anti-IL-6 Receptor Monoclonal Antibody, in Taiwan (October)

Launch of Phesgo®, antineoplastic agent / anti-HER2 humanized monoclonal antibody /hyaluronic acid degrading enzyme combination drug (November)

Abolished the business term of its research subsidiary in Singapore, Chugai Pharmabody Research Pte. Ltd., and decided to expand its middle molecule drug discovery functions as a permanent overseas drug discovery research base (February)

Approval of a humanized complement inhibitor C5 monoclonal antibody (Chinese product name: 派圣凯®) for paroxysmal nocturnal hemoglobinuria in China (February)

Launch of PiaSky® for Injection 340 mg, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody (May)

European approval of PiaSky®, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis (PNH) (September)

Galderma receives US approval for NEMLUVIO® (nemolizumab) created by Chugai, for the treatment of moderate to severe atopic dermatitis by Galderma (December)

Approval of Lunsumio®, antineoplastic agent / anti-CD20/CD3 bispecific antibody (December)